Esperion Therapeutis.Inc. buy nadine86
Start price
11.05.23
/
50%
€1.37
Target price
11.06.23
-
Performance (%)
-6.13%
End price
12.06.23
€1.29
Summary
This prediction ended on 12.06.23 with a price of €1.29. With a performance of -6.13%, the BUY prediction by nadine86 finished with a loss. nadine86 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | - | - | - | - |
| iShares Core DAX® | 0,85 % | 0,39 % | 2,53 % | 52,00 % |
| iShares Nasdaq 100 | -0,99 % | -4,40 % | 25,15 % | 77,54 % |
| iShares Nikkei 225® | -1,78 % | -11,22 % | 44,40 % | 64,68 % |
| iShares S&P 500 | 0,06 % | 0,78 % | 20,95 % | 63,01 % |
Comments by nadine86 for this prediction
In the thread Trading Esperion Therapeutis.Inc.
Die von nadine86 gewählte maximale Laufzeit wurde überschritten